

EULAR 2026 Congress

June 3–6, 2026
London, UK



TOP ABSTRACTS

To help navigate the exciting content being presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, June 3–6, 2026, London, UK, the PsOPsA Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in psoriatic disease.

EULAR 2026: Top abstracts in psoriatic disease

June 3–6, 2026

Oral presentations: Wednesday, June 3

Abstract	Title	Presenter	Time (BST)
OP069 View	Ixekizumab and concomitant tirzepatide achieved early disease control in adults with psoriatic arthritis and obesity/overweight: Phase 3b TOGETHER-PsA trial	Laura C. Coates	16:40–16:50
OP070 View	Dietary interventions in psoriatic arthritis (DIPSA): A randomized controlled clinical trial	Lih Eder	16:50–17:00
OP073 View	Efficacy and safety of izokibep, a novel IL-17a inhibitor, in patients with active psoriatic arthritis: Week 52 results from a randomised, double-blind, placebo-controlled, multicentre, phase 2b/3 study	Philip J. Mease	17:20–17:30
OP074 View	Treatment with glucagon-like peptide-1 receptor agonists is associated with lower disease activity and pain in psoriatic arthritis independent of weight change	Pankti Mehta	17:30–17:40
OP075 View	Structural damage progression and clinical response to guselkumab in participants with active and erosive psoriatic arthritis: Post hoc analysis at Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study	Christopher T. Ritchlin	17:40–17:50

Oral presentations: Thursday, June 4

Abstract	Title	Presenter	Time (BST)
OP0180 View	The development and validation of a diagnostic ultrasound enthesitis score (DUET) for psoriatic arthritis	Sibel Aydin	08:15–08:25
OP0181 View	Impact of biologic therapies and targeted synthetic DMARDs on major adverse cardiovascular events in psoriatic arthritis	Milad Heydari-Kamjani	08:25–08:35
OP0184 View	Phase 2b trial of the selective TYK2 inhibitor zasocitinib (TAK-279) in active psoriatic arthritis: Biomarkers associated with pathway modulation, disease activity and clinical responses	Iain B. McInnes	08:55–09:05
OP0185 View	Treatment retention and clinical remission in 787 real-world patients with psoriatic arthritis treated with bimekizumab: Results from 12 registries in the European Spondyloarthritis Research Collaboration Network	Louise Majormoen Nielung	09:05–09:15
OP0186 View	Effect of guselkumab and golimumab combination therapy on magnetic resonance imaging-detected inflammation and damage in phalangeal joints of the hands and feet and entheses of the heels among participants with active psoriatic arthritis: Findings from the phase 2a AFFINITY study	Mikkel Østergaard	09:15–09:25

OP0187 View	Lighten the load: Artificial intelligence reveals body mass index outranks treatment in one-year psoriatic arthritis outcomes—findings from the SPEED trial	Alexandre Garaïman	09:25–09:35
---------------------------------------	---	--------------------	-------------

Oral presentations: Saturday, June 6

Abstract	Title	Presenter	Time (BST)
LB0001 View	Bimekizumab efficacy & safety versus risankizumab in patients with active psoriatic arthritis: 16-week results from a head-to-head, multicentre, randomised, phase 3b study (BE BOLD)	Joseph F. Merola	12:00–12:10

Posters

Abstract	Title	Presenter	Date and time (BST)
POS0045 View	Persistence, effectiveness, safety, and patient reported impact of guselkumab and IL-17 inhibitors in psoriatic arthritis: Full population results of the PsABIOnd global observational study over 12 months	Laure Gossec	Wednesday, June 3, 15:30–15:36
POS0047 View	Long-term efficacy and safety of risankizumab for csDMARD-IR patients with active psoriatic arthritis: 244-week results from the KEEPSAKE 1 trial	Frank Behrens	Wednesday, June 3, 15:42–15:48
POS0048 View	Bimekizumab inhibited radiographic progression regardless of baseline characteristics in bDMARD-naïve patients with active psoriatic arthritis: 3-year results from a phase 3 study and its open-label extension	Philipp Sewerin	Wednesday, June 3, 15:48–15:54
POS0051 View	Characteristics influencing the prevention of psoriatic arthritis with secukinumab in patients with moderate to severe plaque psoriasis: 5-year real-world results from the SERENA study	Uta Kiltz	Wednesday, June 3, 16:06–16:12
POS0052 View	Icotrokinra, a targeted oral peptide, in participants with moderate-to-severe plaque psoriasis and psoriatic arthritis: Results from a pooled analysis of the phase 3 ICONIC-LEAD, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 trials	Iain B. McInnes	Wednesday, June 3, 16:12–16:18
POS0445 View	Bimekizumab long-term incidence of psoriatic arthritis symptoms and psoriatic arthritis adverse events in patients with psoriasis and risk factors for disease progression	Joseph F. Merola	Wednesday, June 3, from 16:50
POS0453 View	Psoriasis patients at risk for transition to psoriatic arthritis: Early characterization of the STOP PsA at-risk cohort	Victoria Konzett	Wednesday, June 3, 15:30–15:40
POS0456 View	Long-term follow-up of patients in the golimumab and methotrexate versus placebo and methotrexate in early, untreated psoriatic arthritis (GOLMePsA) trial	Katya Meridor	Wednesday, June 3, from 16:00
POS0460 View	Disease burden and comorbidities in patients with psoriatic arthritis and concomitant obesity - a pooled analysis of three clinical trials	Lihi Eder	Wednesday, June 3, from 15:30

POS0471 View	Psoriatic skin and nail outcomes with guselkumab treatment in participants with active and erosive psoriatic arthritis: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study	Joseph F. Merola	Wednesday, June 3, 15:30–15:30
POS0476 View	Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor: Pooled safety and adverse events of special interest in the phase 3 POETYK PsA-1 and PsA-2 trials	Joseph F. Merola	Wednesday, June 3, from 15:30
POS0477 View	Effects of guselkumab on patient-reported outcomes in biologic-naïve participants with active and erosive psoriatic arthritis: Results through Week 24 of the phase 3b, randomized, double-blind, placebo-controlled APEX study	Proton Rahman	Wednesday, June 3, from 15:40
POS0483 View	Comparative effectiveness of risankizumab versus tumour necrosis factor inhibitors or interleukin-17 inhibitors on joint outcomes in biologic-naïve patients with psoriatic arthritis: A global real-world study	Philip J. Mease	Wednesday, June 3, from 16:50
POS0490 View	Efficacy of apremilast in early oligoarticular psoriatic arthritis by baseline active joint count: A <i>post-hoc</i> analysis of the FOREMOST study	Laura C. Coates	Wednesday, June 3, 15:50–16:00
POS0492 View	Efficacy and safety of guselkumab in participants with active psoriatic arthritis and inadequate response/intolerance to one prior tumor necrosis factor inhibitor through 1 year of the SOLSTICE study	Joseph F. Merola	Wednesday, June 3, from 16:00
POS0493 View	Impact of disease duration on the treatment effect of secukinumab in the prevention of psoriatic arthritis in patients with moderate to severe psoriasis: A 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies	Diamant Thaçi	Wednesday, June 3, from 16:50
POS0498 View	Bimekizumab treatment resulted in rapid response that was associated with clinically important improvements in patient-reported outcomes up to 3 years in patients with psoriatic arthritis	Laure Gossec	Wednesday, June 3, from 16:50
POS0502 View	Efficacy and safety of subcutaneous ustekinumab in pediatric participants with active juvenile psoriatic arthritis: Results of the open-label, phase 3 PSUMMIT-Jr study through Week 52	Nicolino Ruperto	Wednesday, June 3, 16:20–16:30
POS0288 View	Efficacy and safety of deucravacitinib through Week 52 in patients with active psoriatic arthritis: Impact of concomitant methotrexate use in a pooled analysis of the pivotal phase 3 POETYK PsA trials	Joseph F. Merola	Friday, June 5, 13:36–13:42
POS0291 View	Quantifying the obesity-psoriatic arthritis nexus: Prevalence, incidence, and comorbidities from 19.9 million US patients (2018-2024)	Jeffrey R. Curtis	Friday, June 5, 13:54–14:00
POS0293 View	Differential molecular profiles in psoriatic arthritis: The potential of metabolomics to predict treatment outcomes	Mieke L. M. Bentvelzen	Friday, June 5, 14:06–14:12



EULAR 2026

Follow us on X to keep up to date
with the latest from the congress

@Psoriasis_Hub



PsOPsA Hub

Brought to you by

